EE04238B1 - Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias - Google Patents
Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapiasInfo
- Publication number
- EE04238B1 EE04238B1 EEP200000041A EEP200000041A EE04238B1 EE 04238 B1 EE04238 B1 EE 04238B1 EE P200000041 A EEP200000041 A EE P200000041A EE P200000041 A EEP200000041 A EE P200000041A EE 04238 B1 EE04238 B1 EE 04238B1
- Authority
- EE
- Estonia
- Prior art keywords
- therapy
- substituted
- preparation
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702799A SE9702799D0 (sv) | 1997-07-25 | 1997-07-25 | New compounds |
| PCT/SE1998/001390 WO1999005134A1 (en) | 1997-07-25 | 1998-07-15 | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200000041A EE200000041A (et) | 2000-10-16 |
| EE04238B1 true EE04238B1 (et) | 2004-02-16 |
Family
ID=20407828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200000041A EE04238B1 (et) | 1997-07-25 | 1998-07-15 | Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US6313118B1 (is) |
| EP (1) | EP1000048B1 (is) |
| JP (1) | JP3895923B2 (is) |
| KR (1) | KR20010022171A (is) |
| CN (1) | CN1270585A (is) |
| AR (2) | AR013370A1 (is) |
| AT (1) | ATE228510T1 (is) |
| AU (1) | AU739569B2 (is) |
| BR (1) | BR9811042A (is) |
| CA (1) | CA2296518A1 (is) |
| DE (1) | DE69809755T2 (is) |
| DK (1) | DK1000048T3 (is) |
| DZ (1) | DZ2569A1 (is) |
| EE (1) | EE04238B1 (is) |
| ES (1) | ES2187983T3 (is) |
| HR (1) | HRP980404B1 (is) |
| HU (1) | HUP0004334A3 (is) |
| ID (1) | ID24583A (is) |
| IL (1) | IL134108A0 (is) |
| IS (1) | IS5358A (is) |
| MA (1) | MA26521A1 (is) |
| NO (1) | NO315609B1 (is) |
| NZ (1) | NZ502384A (is) |
| PL (1) | PL338563A1 (is) |
| PT (1) | PT1000048E (is) |
| RU (1) | RU2194696C2 (is) |
| SE (1) | SE9702799D0 (is) |
| SI (1) | SI1000048T1 (is) |
| SK (1) | SK283918B6 (is) |
| TN (1) | TNSN98141A1 (is) |
| TR (1) | TR200000229T2 (is) |
| TW (1) | TW438781B (is) |
| UA (1) | UA69389C2 (is) |
| WO (1) | WO1999005134A1 (is) |
| YU (1) | YU2300A (is) |
| ZA (1) | ZA986588B (is) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| SE9900190D0 (sv) * | 1999-01-22 | 1999-01-22 | Astra Ab | New compounds |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0002729D0 (sv) * | 2000-07-20 | 2000-07-20 | Astrazeneca Ab | Novel compound form |
| AR034206A1 (es) * | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos |
| SE0102856D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | A new method |
| SE0103644D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
| US7101881B2 (en) * | 2003-06-11 | 2006-09-05 | Pfizer Inc | Tetrahydroquinolines |
| SE0301798D0 (sv) * | 2003-06-19 | 2003-06-19 | Astrazeneca Ab | New use IV |
| SE0301794D0 (sv) * | 2003-06-19 | 2003-06-19 | Astrazeneca Ab | New use III |
| BRPI0511195A (pt) * | 2004-05-21 | 2007-12-04 | Pfizer Prod Inc | tetraidronaftilpiperazinas como antagonistas da 5-ht1b, agonistas inversos e agonistas parciais |
| ATE499147T1 (de) * | 2004-09-30 | 2011-03-15 | Hoffmann La Roche | Zusammensetzungen und verfahren zur behandlung kognitiver störungen |
| US20080033050A1 (en) * | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
| WO2008130323A1 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel 8-piperazine-tetrahydronaphtalene derivatives for the treatment of pain |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| WO2008130321A2 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain |
| WO2008130322A1 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel 5-heterocyclyl-chromane derivatives for the treatment of pain |
| WO2008130319A2 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain |
| EP2098511A1 (en) | 2008-03-07 | 2009-09-09 | Solvias AG | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring |
| TWI488854B (zh) | 2008-06-20 | 2015-06-21 | Astrazeneca Ab | 二苯并噻氮呯衍生物及其用途 |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| EA029430B1 (ru) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3919624A1 (de) | 1989-06-15 | 1990-12-20 | Boehringer Ingelheim Kg | Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| PT533268E (pt) | 1991-09-18 | 2002-02-28 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d |
| DK148392D0 (da) | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
| ATE201403T1 (de) * | 1993-03-16 | 2001-06-15 | Pfizer | Naphtalinderivate |
| EP0639568A1 (en) * | 1993-08-19 | 1995-02-22 | Novo Nordisk A/S | Piperidine compounds, their preparation and use in the treatment of neurodegenerative disorders |
| EP0724580A1 (en) | 1993-10-19 | 1996-08-07 | Smithkline Beecham Plc | Benzanilide derivatives as 5ht-1d receptor antagonists |
| SE9601110D0 (sv) | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
-
1997
- 1997-07-25 SE SE9702799A patent/SE9702799D0/xx unknown
-
1998
- 1998-07-13 TW TW087111330A patent/TW438781B/zh not_active IP Right Cessation
- 1998-07-15 TR TR2000/00229T patent/TR200000229T2/xx unknown
- 1998-07-15 JP JP2000504131A patent/JP3895923B2/ja not_active Expired - Fee Related
- 1998-07-15 CN CN98809246A patent/CN1270585A/zh active Pending
- 1998-07-15 PT PT98934104T patent/PT1000048E/pt unknown
- 1998-07-15 RU RU2000104802/04A patent/RU2194696C2/ru not_active IP Right Cessation
- 1998-07-15 PL PL98338563A patent/PL338563A1/xx unknown
- 1998-07-15 US US09/171,577 patent/US6313118B1/en not_active Expired - Fee Related
- 1998-07-15 IL IL13410898A patent/IL134108A0/xx unknown
- 1998-07-15 DE DE69809755T patent/DE69809755T2/de not_active Expired - Fee Related
- 1998-07-15 CA CA002296518A patent/CA2296518A1/en not_active Abandoned
- 1998-07-15 HU HU0004334A patent/HUP0004334A3/hu unknown
- 1998-07-15 UA UA2000021064A patent/UA69389C2/uk unknown
- 1998-07-15 EP EP98934104A patent/EP1000048B1/en not_active Expired - Lifetime
- 1998-07-15 ES ES98934104T patent/ES2187983T3/es not_active Expired - Lifetime
- 1998-07-15 AT AT98934104T patent/ATE228510T1/de not_active IP Right Cessation
- 1998-07-15 MA MA25169A patent/MA26521A1/fr unknown
- 1998-07-15 EE EEP200000041A patent/EE04238B1/xx not_active IP Right Cessation
- 1998-07-15 KR KR1020007000743A patent/KR20010022171A/ko not_active Ceased
- 1998-07-15 SK SK1883-99A patent/SK283918B6/sk unknown
- 1998-07-15 WO PCT/SE1998/001390 patent/WO1999005134A1/en not_active Ceased
- 1998-07-15 NZ NZ502384A patent/NZ502384A/en unknown
- 1998-07-15 AU AU83703/98A patent/AU739569B2/en not_active Ceased
- 1998-07-15 DK DK98934104T patent/DK1000048T3/da active
- 1998-07-15 BR BR9811042-0A patent/BR9811042A/pt not_active IP Right Cessation
- 1998-07-15 ID IDW20000122A patent/ID24583A/id unknown
- 1998-07-15 YU YU2300A patent/YU2300A/sh unknown
- 1998-07-15 SI SI9830343T patent/SI1000048T1/xx unknown
- 1998-07-22 DZ DZ980179A patent/DZ2569A1/xx active
- 1998-07-23 ZA ZA986588A patent/ZA986588B/xx unknown
- 1998-07-23 TN TNTNSN98141A patent/TNSN98141A1/fr unknown
- 1998-07-23 HR HR980404A patent/HRP980404B1/xx not_active IP Right Cessation
- 1998-07-24 AR ARP980103667A patent/AR013370A1/es unknown
-
2000
- 2000-01-24 IS IS5358A patent/IS5358A/is unknown
- 2000-01-24 NO NO20000356A patent/NO315609B1/no not_active IP Right Cessation
-
2001
- 2001-07-10 US US09/902,000 patent/US6410532B2/en not_active Expired - Fee Related
- 2001-07-10 US US09/902,123 patent/US6534652B2/en not_active Expired - Fee Related
-
2004
- 2004-10-25 AR ARP040103875A patent/AR046193A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE04238B1 (et) | Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias | |
| EE04399B1 (et) | Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis | |
| EE04021B1 (et) | 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks | |
| EE9700043A (et) | Asendatud oksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid | |
| EE200200046A (et) | 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon | |
| EE04965B1 (et) | Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon | |
| HUP0301101A3 (en) | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | |
| FI973828A0 (fi) | Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi | |
| IT1283102B1 (it) | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele | |
| EE9900296A (et) | Suure bioomastatavusega fenofibraatide ravimkoostis ja meetod selle valmistamiseks | |
| EE04463B1 (et) | 3-arüülpropaanhappe derivaadid ja nende analoogid, nende valmistamise meetod, neid sisaldavad ravimkoostised ja ühendid kasutamiseks ravis | |
| BR9702147A (pt) | Composição farmacéutica uso de uma composição farmacéutica e processo para o tratamento da dor associada com escarificação periodontal e para a preparação de uma composição farmacéutica | |
| BR9610248A (pt) | Composto composição farmacêutica processos para o tratamento da dor e para a preparação de um composto e uso do composto | |
| EE03613B1 (et) | Omeprasooli naatriumisool,selle valmistamise protsess,seda sisaldav ravimkoostis ja selle kasutamine seedetrakti häirete ravimiseks | |
| EE9700241A (et) | Farmatseutiline kompositsioon transdermaalseks manustamiseks | |
| EE9700060A (et) | 2-arüül-asendatud püridiinid,nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid | |
| NO305903B1 (no) | Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater | |
| AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
| EE03825B1 (et) | 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
| EE9800200A (et) | Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon | |
| EE04119B1 (et) | Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod | |
| DE4495520T1 (de) | Verfahren und pharmazeutische Zusammensetzung zum zielgerichten Anwenden von Wirkstoffen | |
| EE04263B1 (et) | Farmatseutiline kompositsioon piperidinoalkanoolantihistamiini ja selle derivaatide biosaadavuse suurendamiseks ning allergiliste reaktsioonide raviks patsiendil | |
| EE9600023A (et) | Fenüültsükloheksüülkarboksüülhappeamiidid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud ühendeid sisaldavad ravimid ja nende valmistamismeetod | |
| BR0012184B1 (pt) | compostos derivados de indol, formulação farmacêutica, e, composição e uso dos compostos na fabricação de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC1A | Change of owner name | ||
| KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20050715 |